Compare Becton Dickinson and Co (BDX) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Transocean Ltd — how do they compare? Becton Dickinson and Co trades at $156.17 (market cap $41.51B), while Transocean Ltd trades at $5.2 (market cap $5.88B). The key difference: Becton Dickinson and Co is far larger — about 7.1× Transocean Ltd's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| BDX | RIG | |
|---|---|---|
Market Cap | $41.51B | $5.88B |
Sector | Health | Technology |
52-Week High | $185.39 | $7.58 |
52-Week Low | $135.49 | $2.55 |
Enterprise Value | $57.97B | $10.82B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Transocean Ltd. (RIG) trades at $5.37, up 3.27% today, with a bullish technical signal from moving averages. The company reported a net loss of $2.92 billion in 2025, but revenue grew to $3.97 billion, and recent contract wins, including a $1 billion deal with Equinor, bolster its backlog. The pending merger with Valaris Limited aims to reduce leverage and unlock synergies.
The outlook is mixed; analyst consensus is a Buy with a $7.00 price target, but persistent net losses and high debt pose risks. Upside depends on successful merger integration and improved profitability, while oil price volatility and execution challenges remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
